Audit: QRS - Goldenseal for Health & Longevity

Audit conducted on 15/08/2026 19:40 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, benefit/risk tiers, gates, markers and cadence all trace to ER lines 274–297, 315–348, 366–414, 434–440.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“no study has compared timings”, “Described by traditional and reference sources, not by trials”, “No controlled human trial has tested a health outcome” mirror ER wording.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain absolute framing; the warfarin qualifier “unless anticoagulation is monitored closely” is preserved from ER line 296.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from ER “Populations who should avoid Goldenseal”; Key Interactions from the ER interaction bullets; no modifying factors were promoted.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, declarative register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Thresholds and ranges given without alarmism; qualitative markers frame self-assessment constructively.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	No imperatives; cadence and markers are stated descriptively.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Cadence is phrased as observation (“Baseline before a first course; no repeat testing for a 7–14 day course”), not instruction.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”/”advise”/”should” constructions in populated variables.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in any populated variable.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms present (CYP3A4, Child-Pugh) are carried from the ER and are load-bearing for the decision gates.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are reduced to key facts; ER explanations and citations are stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; no direct address in populated content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker ranges, cycling protocol and third-party-testing framing target this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Three-times-daily dosing, baseline lab panel and daily glucose checks are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes willingness to obtain lab work and reconcile medications.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance leads with the interaction risk being the best-established effect, which is the decision-relevant signal for a supplement-using audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“alanine aminotransferase”, “hyperbilirubinaemia”, “adverse”-register terminology used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings match the template byte-for-byte (lines 445, 486, 530, 552, 576, 610, 639, 643–645, 743).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#* and qualitative_item# spans are expanded to 6 rows and 6 items respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" spans are untouched; CSS and structure are identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	The only empty source sub-sections are the High and Medium benefit tiers, which item 12.5 explicitly governs (display:none, not empty-state phrasing).
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard short-course oral protocol”, “Best time of day”, “Topical and mucosal approach” match ER lines 317, 321, 323; interaction labels match ER lines 274–286.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels use the ER’s own phrases (“mucosal and digestive effects”, “Enzyme inhibition”, ER lines 346, 368); marker names match the ER biomarker table verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points in the file; the ER’s “⚠️ Conflicted” marker was correctly not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to key facts; the remaining length in the gates is mandated by items 8.5/9.5, which require the parenthetical drug lists and thresholds be preserved.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the title text on line 2 precedes the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: goldenseal_2026-0825-1749_Opus_ER.md, matching the ER’s own filename frontmatter field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0815-1934, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no context-window or other qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: goldenseal_2026-0825-1749_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed across all eleven keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Goldenseal for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Goldenseal for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0815-1934 → “08/15/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s alternate-names line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 436–440: traditional use, in-vitro activity, absence of outcome trials, the interaction effect, and the rodent liver finding.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four clauses maps to a distinct sentence in the ER Conclusion (lines 436, 438).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “slowing the breakdown of many prescription medicines” replaces the CYP terminology used elsewhere in the sheet.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates; “very high intakes” is qualitative.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from “Populations who should avoid Goldenseal”, ER lines 288–297.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 8 ER populations are represented, in ER order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements inside the stop_items span (lines 555–571).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationale clauses (“because of hydrastine’s uterine-stimulant activity”, “where a CYP3A4 shift can cause rejection or toxicity”) are stripped; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(total bilirubin above 3 mg/dL)”, “Child-Pugh Class B or C”, “above three times the upper reference limit” and “under 2 years” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from ER lines 274–286.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 7 ER interaction bullets are present; none duplicates a contraindication item, which are population/condition-based rather than drug-class-based.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the caution_items span (lines 579–600).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Consequence clauses (myopathy, bradycardia, serotonergic excess) and the Yamaura and Adiwidjaja citations are all stripped; no dash-trailing clauses remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All six ER parenthetical drug/supplement lists are retained in full; “Other interventions” retains surgery, contrast imaging and oncology regimen.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names seven interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Sourced from ER “Therapeutic Protocol”, lines 315–337.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose/duration, timing, and the topical alternative — the three bullets that determine what a person actually does.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER contains more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine variables populated; e.g. “0.5–1 g dried root powder, three times daily” and “Or 2–4 mL of 1:5 tincture … for 7–14 days” from ER line 317.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Mucosal/digestive onset and enzyme-inhibition onset from ER line 368; reversal window from ER line 346.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The benefit-linked mucosal/digestive effect leads, followed by the onset and then the reversal of the enzyme effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Within days”, “Several days” / “Near-maximal by 14 days of continuous use”, “Roughly 14 days” all trace to ER lines 346 and 368.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 368), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Sourced from ER lines 138–176.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (lines 532–545).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER’s own benefit headings; MIC figures, cytokine names and the Cech/Hwang citations are all stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in either populated benefit tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s High and Medium tiers contain no benefits; both spans carry style="display: none" and are empty (lines 532–533).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Sourced from ER lines 192–256.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 612–633).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER’s own risk headings; AUC figures, the debrisoquine ratio, the NTP dose and the “⚠️ Conflicted” qualifier are all stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Sourced from ER “Monitoring Protocol & Defining Success”, lines 392–405.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 6 rows of the ER biomarker table are present with names, targets and rationale intact.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, no repeat for 7–14 days, 4–8 week and 6–12 month repeats, daily glucose on metformin and weekly coagulation on warfarin — all from ER line 396.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the qualitative-marker list at ER lines 409–414.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 ER qualitative markers are present, in ER order.

Issues 15/08/2026 19:40

Pass rate 100.00%. No issues found.